Navigating the Complexities of Personalized Prostate Cancer Care: Insights for Oncology Managed Care

Program Description

Prostate cancer is the most common disease burdening men across the United States, and it is the second leading cause of cancer-related deaths in men. In recent years, the use of anti-androgen therapy has been shown to be effective in clinical trials with use alongside PARP inhibitors. Earlier addition of anti-androgen therapy has been employed to mitigate mortality associated with metastatic castration-resistant prostate cancer (mCRPC). Yet, rates of prostate cancer are continuing to rise due to health disparities across the United States, such as socioeconomic challenges, environmental exposures, and genetic factors. Recognizing potential signs and symptoms of prostate cancer is key to implementing more timely treatment for patients at heightened risk and ensuring that treatment selection is personalized based on patient preference, molecular testing, and accessibility. The activity will review emerging research in cost-effective prostate cancer treatment through the optimization of guideline-directed medical therapies. Key points within this article will support managed care pharmacists in advocating for adherence to medications as well as access to cost-effective regimens to appropriately treat the condition and enhance men’s quality of life.

Target audience: Managed care pharmacists, oncology pharmacists

Type of activity: Application
Release date: December 1, 2025
Expiration date: December 19, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Assess the evolving treatment landscape for prostate cancer and the use of molecular testing in personalizing therapy to optimize patient outcomes
• Provide recent clinical and safety evidence for novel and emerging treatments, including anti-androgens, PARP inhibitors, and combination regimens for prostate cancer
• Investigate the economic considerations of advanced prostate cancer therapies and strategies to improve access, optimize outcomes, and manage costs in the context of managed care

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEU) under the ACPE universal activity number 0290-0000-25-371-H01-P. The activity is available for CE credit through December 19, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

FACULTY

Kristen Nymberg, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose: Advisory Boards: Seagen Inc, Astellas Pharma Global Development Inc

All of the relevant financial relationships listed for this individual have been mitigated.

The following individuals have no relevant financial relationships with ineligible companies to disclose:

MEDICAL WRITER/EDITORIAL SUPPORT

Rachel Feaster, PharmD, BCOP, BCPS

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms